# Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

> **NCT04816604** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.** · enrollment: 74 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** GB002 (seralutinib)
- **DEVICE:** Generic Dry Powder Inhaler

## Key facts

- **NCT ID:** NCT04816604
- **Lead sponsor:** GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-05
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04816604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04816604, "Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04816604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*